177 related articles for article (PubMed ID: 23545115)
1. Modified lipoproteins as biomarkers of cardiovascular risk in diabetes mellitus.
Sánchez-Quesada JL; Pérez A
Endocrinol Nutr; 2013 Nov; 60(9):518-28. PubMed ID: 23545115
[TBL] [Abstract][Full Text] [Related]
2. Modified low-density lipoproteins as biomarkers in diabetes and metabolic syndrome.
Rivas-Urbina A; Benitez S; Perez A; Sanchez-Quesada JL
Front Biosci (Landmark Ed); 2018 Jan; 23(7):1220-1240. PubMed ID: 28930596
[TBL] [Abstract][Full Text] [Related]
3. [Front line of oxidized lipoproteins: role of oxidized lipoproteins in atherogenesis and cardiovascular disease risk].
Yoshida H
Rinsho Byori; 2010 Jun; 58(6):622-30. PubMed ID: 20662275
[TBL] [Abstract][Full Text] [Related]
4. [Lipoprotein glycation and glycoxidation: their importance in diabetes mellitus].
Actis Dato SM; Rebolledo OR
Medicina (B Aires); 2000; 60(5 Pt 1):645-56. PubMed ID: 11188909
[TBL] [Abstract][Full Text] [Related]
5. Atherosclerotic risk factors in cardiovascular disease.
LaRosa JC
J Reprod Med; 1986 Sep; 31(9 Suppl):906-12. PubMed ID: 3772910
[TBL] [Abstract][Full Text] [Related]
6. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.
Tani S; Matsumoto M; Nagao K; Hirayama A
J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623
[TBL] [Abstract][Full Text] [Related]
7. Small, dense low-density-lipoproteins and the metabolic syndrome.
Rizzo M; Berneis K
Diabetes Metab Res Rev; 2007 Jan; 23(1):14-20. PubMed ID: 17080469
[TBL] [Abstract][Full Text] [Related]
8. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
Nicholls SJ; Lundman P; Tardif JC
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
[TBL] [Abstract][Full Text] [Related]
9. Increase in oxidized low-density lipoprotein level according to hyperglycemia in patients with cardiovascular disease: A study by structure equation modeling.
Yamada T; Ogawa K; Tanaka TD; Nagoshi T; Minai K; Ogawa T; Kawai M; Yoshimura M
Diabetes Res Clin Pract; 2020 Mar; 161():108036. PubMed ID: 32006643
[TBL] [Abstract][Full Text] [Related]
10. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?
Verhoye E; Langlois MR;
Clin Chem Lab Med; 2009; 47(2):128-37. PubMed ID: 19099526
[TBL] [Abstract][Full Text] [Related]
11. Measures of oxidative stress.
Tsimikas S
Clin Lab Med; 2006 Sep; 26(3):571-90, v-vi. PubMed ID: 16938585
[TBL] [Abstract][Full Text] [Related]
12. Study of changes in antioxidant enzymes status in diabetic post menopausal group of women suffering from cardiovascular complications.
Kumawat M; Sharma TK; Singh N; Ghalaut VS; Vardey SK; Sinha M; Kaushik GG
Clin Lab; 2012; 58(3-4):203-7. PubMed ID: 22582492
[TBL] [Abstract][Full Text] [Related]
13. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
14. Diabetic dyslipidemia.
Chahil TJ; Ginsberg HN
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):491-510, vii-viii. PubMed ID: 16959582
[TBL] [Abstract][Full Text] [Related]
15. Are plasma lipoproteins responsible for the excess atherosclerosis in diabetes?
Nikkilä EA
Acta Endocrinol Suppl (Copenh); 1985; 272():27-30. PubMed ID: 3869424
[TBL] [Abstract][Full Text] [Related]
16. Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis.
Viigimaa M; Abina J; Zemtsovskaya G; Tikhaze A; Konovalova G; Kumskova E; Lankin V
Blood Press; 2010 Jun; 19(3):164-8. PubMed ID: 20429692
[TBL] [Abstract][Full Text] [Related]
17. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
Oki JC
Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
[TBL] [Abstract][Full Text] [Related]
18. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein size and cardiovascular risk assessment.
Rizzo M; Berneis K
QJM; 2006 Jan; 99(1):1-14. PubMed ID: 16371404
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold?
Taleb A; Tsimikas S
Expert Rev Cardiovasc Ther; 2012 Apr; 10(4):399-402. PubMed ID: 22458571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
